It is also likely that the cytokine storm triggered by COVID-19 takes part in the development of GBS in SARS-CoV-2 infected patients, as it has been reported that cerebrospinal fluid of patients with GBS is characterized by elevated IFN-γ and their serum, characterized by elevated TNF-α, which are cytokines that are also peaked in the setting of COVID-19 (108). This evidence concerns the gene IFNG and Guillain-Barre syndrome.